Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure

The ECOG experience in over 1200 patients

Justin M. Watts, Xin Victoria Wang, Mark R. Litzow, Selina M. Luger, Hillard M. Lazarus, Peter A. Cassileth, Hugo F. Fernandez, Dan Douer, Lynette Zickl, Elisabeth M. Paietta, Jacob M. Rowe, Martin S. Tallman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

Original languageEnglish (US)
Pages (from-to)901-906
Number of pages6
JournalLeukemia Research
Volume38
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Acute Myeloid Leukemia
Young Adult
Recurrence
Karyotype
Chromosome Aberrations
Survival

Keywords

  • Acute myeloid leukemia
  • Clinical trials
  • Late relapse
  • Normal cytogenetics
  • Outcomes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure : The ECOG experience in over 1200 patients. / Watts, Justin M.; Wang, Xin Victoria; Litzow, Mark R.; Luger, Selina M.; Lazarus, Hillard M.; Cassileth, Peter A.; Fernandez, Hugo F.; Douer, Dan; Zickl, Lynette; Paietta, Elisabeth M.; Rowe, Jacob M.; Tallman, Martin S.

In: Leukemia Research, Vol. 38, No. 8, 2014, p. 901-906.

Research output: Contribution to journalArticle

Watts, JM, Wang, XV, Litzow, MR, Luger, SM, Lazarus, HM, Cassileth, PA, Fernandez, HF, Douer, D, Zickl, L, Paietta, EM, Rowe, JM & Tallman, MS 2014, 'Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients', Leukemia Research, vol. 38, no. 8, pp. 901-906. https://doi.org/10.1016/j.leukres.2014.05.018
Watts, Justin M. ; Wang, Xin Victoria ; Litzow, Mark R. ; Luger, Selina M. ; Lazarus, Hillard M. ; Cassileth, Peter A. ; Fernandez, Hugo F. ; Douer, Dan ; Zickl, Lynette ; Paietta, Elisabeth M. ; Rowe, Jacob M. ; Tallman, Martin S. / Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure : The ECOG experience in over 1200 patients. In: Leukemia Research. 2014 ; Vol. 38, No. 8. pp. 901-906.
@article{b36540404b854598a47ffd910582bd83,
title = "Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: The ECOG experience in over 1200 patients",
abstract = "We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1{\%} of CR1 patients; 3.3{\%} of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.",
keywords = "Acute myeloid leukemia, Clinical trials, Late relapse, Normal cytogenetics, Outcomes",
author = "Watts, {Justin M.} and Wang, {Xin Victoria} and Litzow, {Mark R.} and Luger, {Selina M.} and Lazarus, {Hillard M.} and Cassileth, {Peter A.} and Fernandez, {Hugo F.} and Dan Douer and Lynette Zickl and Paietta, {Elisabeth M.} and Rowe, {Jacob M.} and Tallman, {Martin S.}",
year = "2014",
doi = "10.1016/j.leukres.2014.05.018",
language = "English (US)",
volume = "38",
pages = "901--906",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure

T2 - The ECOG experience in over 1200 patients

AU - Watts, Justin M.

AU - Wang, Xin Victoria

AU - Litzow, Mark R.

AU - Luger, Selina M.

AU - Lazarus, Hillard M.

AU - Cassileth, Peter A.

AU - Fernandez, Hugo F.

AU - Douer, Dan

AU - Zickl, Lynette

AU - Paietta, Elisabeth M.

AU - Rowe, Jacob M.

AU - Tallman, Martin S.

PY - 2014

Y1 - 2014

N2 - We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

AB - We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

KW - Acute myeloid leukemia

KW - Clinical trials

KW - Late relapse

KW - Normal cytogenetics

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84904577671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904577671&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.05.018

DO - 10.1016/j.leukres.2014.05.018

M3 - Article

VL - 38

SP - 901

EP - 906

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -